$GENFLEET-B(02595.HK) The recent Longbridge lottery rate is acceptable 😌
Overview
GENFLEET-B (2595)
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases...
- Open
- 21.680
- High
- 21.880
- Low
- 19.070
- Prev. Close
- 21.680
- Volume
- 3.71M
- Turnover
- 73.48M
- Avg Price
- 19.798
- Bid/Ask Ratio
- -60.00%
- Amplitude
- 12.96%
- 52wk High
- 52.900
- Volume Ratio
- 1.56
- Turnover Ratio
- 1.07%
- 52wk Low
- 17.580
- HK Mkt Cap
- 6.74B
- Market CapHKD
- 7.36B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -3.98
- EPSDynamic
- -1.33
- EPSStatic
- --
- BVPS
- 4.86
- P/B
- 3.98
- HK Shares
- 348.46M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 380.80M
- Min lot size
- 200
- Currency
- HKD
GENFLEET-B Analyst Rating
View moreForecast & Rating
Oct 15, 2026- Strong buy80.00%
- Buy20.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 4
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
GenFleet Therapeutics (2595.HK) spiked to HK$21.36 at 09:32 BJ, then fell steadily through the session to close at HK$19.14, down about 11.7% from the prior HK$21.68, settling near the afternoon low of HK$19.07 at 15:50 and below the HK$19.80 full-day average price, a spike-and-fade pattern on 3.70 million shares. The stock had risen 12% in a single session when its GFH276 combination therapies won China clinical clearance and has since given that gain back; multiple brokers rate it buy and the company has filed next-day share-buyback returns repeatedly, neither of which held the price. Q2 2026 revenue was HK$24.53 million, down 49.55% year on year, while the net loss of HK$127.15 million narrowed 66.78% and loss per share of HK$0.3433 improved 76.8%; an operating loss of HK$113.82 million, however, widened 137.24%, so shrinking revenue alongside a larger operating loss frames the pressure. Narrowing losses and the buyback record remain the few supports of the day.
- Nov, 13
GenFleet Therapeutics-B staged a spike-and-fade session, opening at the day's high of HK$23.82 before sliding one-way to HK$21.20 at 14:42 BJ and closing at HK$21.44, about 10% below the prior close of HK$23.82, on HK$61.65 million turnover and a thin 0.80% turnover rate. The move follows a 12% single-day jump driven by China trial approvals for GFH276 combination therapies and a 41.1% response rate in an early-stage pancreatic cancer study, plus more than half a dozen share-buyback next-day disclosure returns since late October; with no fresh announcement today, those gains met profit-taking. Fundamentals remain at an early commercial scale: Q2 2026 revenue was HK$24.53 million, down 49.55% year on year, while the net loss of HK$127.15 million narrowed 66.78% and loss per share of HK$0.3433 narrowed 76.8%, though the operating loss of HK$113.82 million widened 137.24%. The stock sits below MA20 of HK$24.98 and MA60 of HK$27.73, down 4.03% year to date, 59.47% under the April 26 52-week high of HK$52.90 yet 21.96% above the November 2 low of HK$17.58, with PB at 4.42x. While continued buyback disclosures may offer some support.
- Nov, 10
GenFleet Therapeutics-B rose 6.4% to HK$23.96, driven by China clinical trial approvals for multiple combination therapies involving its oral pan-RAS inhibitor GFH276 and by the company's Nov 6 buyback of 220,000 shares for HK$4.86 million. The session traced a dip-and-recover pattern before fading into the close: it touched HK$22.88 in the morning, reached HK$24.40 in the afternoon, then settled at HK$23.96 on HK$39.99 million turnover. Orient Securities and China Universal each added 299,600 shares at about HK$23.44. Despite the rebound, the price remains below its 20-day moving average of HK$25.54 and 60-day MA of HK$28.11, 54.71% below the 52-week high of HK$52.90 and 36.29% above the Nov 2 low of HK$17.58, with a year-to-date gain of 7.25%. Q2 revenue was HK$24.53 million, down 49.55% year on year; net loss narrowed 66.78% to HK$127.15 million while operating loss widened 137.24% to HK$113.82 million. The stock's PB stands at 4.94. Though the clinical and buyback news supported the move, the revenue decline and wider operating loss remain in contrast with the rebound.
- Nov, 9
GenFleet Therapeutics-B opened 7.3% higher at HK$23.40 but faded to close at HK$22.52, up 3.30%, as the company repurchased 220,000 H shares for HK$4.86 million on 6 November, taking cumulative buybacks to 2.9078 million H shares, while its oral pan-RAS inhibitor GFH276 won mainland China trial approvals for multiple combination studies. Second-quarter revenue fell 49.55% year on year to HK$24.53 million; the HK$127.2 million net loss narrowed 66.78%, yet the operating loss widened 137% to HK$113.8 million. The stock is up just 0.81% year to date and sits 57.43% below its 52-week high of HK$52.90, closing under both the MA20 of HK$25.73 and MA60 of HK$28.22. Though the bid rests largely on buybacks and clinical progress, the revenue contraction has yet to turn.
- Nov, 6
Genfleet Therapeutics-B fell 8.33% to HK$21.80 in a high-open, low-close session, fading from an intraday peak of HK$23.02 at 09:40 BJ to a HK$21.68 low at 15:46 BJ on 1.945 million shares, extending the prior session's roughly 7% decline as the market kept unwinding the 12% surge sparked by China trial approvals for multiple GFH276 pan-RAS inhibitor combination therapies. Fundamentals cut both ways: Q2 2026 revenue of HK$24.5 million fell 49.55% year on year and the HK$127.2 million net loss narrowed 66.78%, yet the operating loss widened 137.24%, with ROE at -27.42% and PB at 4.49. Buybacks of 551,000 shares for about HK$11.25 million on 2-3 November, plus separate 299,600-share stake increases by Orient Securities and China Universal Asset Management at roughly HK$23.44, sit above the current price. The stock is 58.79% below its 26 April high of HK$52.90, only 24% above the 2 November 52-week low of HK$17.58, and below its MA20 of HK$26.03 and MA60 of HK$28.37; the narrowing loss and steady buybacks offer some offset, though.
News
PUBT · Genfleet Therapeutics Discloses Share Buyback in HKEX Next Day Return
Market Movers · Genfleet tumbles 12%
PUBT · GenFleet Doses First Patients in China, Australia in GFH276 Combination Trial for Pancreatic Cancer
Weekly Review · Weekly Recap | GENFLEET-B -3.73%, most brokers rate it buy
Market Movers · Genfleet drops 6%
